Dual-glycolipid engineered vaccine platform empowers delivery route customization to intercept tumor lung metastasis.
Pulmonary metastasis remains a lethal challenge, necessitating potent mRNA vaccines to establish proactive immune surveillance. Although lipid nanoparticles (LNPs) are the gold standard for delivery mRNA, the "PEG dilemma"-comprising immunogenicity and poor cellular engagement-critically limits their efficacy. Here, we...